A Randomized Controlled Trial Comparing the Effects of Counseling and Alarm Device on HAART Adherence and Virologic Outcomes

English version České info

Background:
Behavioral interventions that promote adherence to antiretroviral medications may decrease HIV treatment failure. Antiretroviral treatment programs in sub-Saharan Africa confront increasing financial constraints to provide comprehensive HIV care, which include adherence interventions. This study compared the impact of counseling and use of an alarm device on adherence and biological outcomes in a resource-limited setting.

Methods and Findings:
A randomized controlled, factorial designed trial was conducted in Nairobi, Kenya. Antiretroviral-naïve individuals initiating free highly active antiretroviral therapy (HAART) in the form of fixed-dose combination pills (d4T, 3TC, and nevirapine) were randomized to one of four arms: counseling (three counseling sessions around HAART initiation), alarm (pocket electronic pill reminder carried for 6 months), counseling plus alarm, and neither counseling nor alarm. Participants were followed for 18 months after HAART initiation. Primary study endpoints included plasma HIV-1 RNA and CD4 count every 6 months, mortality, and adherence measured by monthly pill count. Between May 2006 and September 2008, 400 individuals were enrolled, 362 initiated HAART, and 310 completed follow-up. Participants who received counseling were 29% less likely to have monthly adherence <80% (hazard ratio [HR] = 0.71; 95% confidence interval [CI] 0.49–1.01; p = 0.055) and 59% less likely to experience viral failure (HIV-1 RNA ≥5,000 copies/ml) (HR 0.41; 95% CI 0.21–0.81; p = 0.01) compared to those who received no counseling. There was no significant impact of using an alarm on poor adherence (HR 0.93; 95% CI 0.65–1.32; p = 0.7) or viral failure (HR 0.99; 95% CI 0.53–1.84; p = 1.0) compared to those who did not use an alarm. Neither counseling nor alarm was significantly associated with mortality or rate of immune reconstitution.

Conclusions:
Intensive early adherence counseling at HAART initiation resulted in sustained, significant impact on adherence and virologic treatment failure during 18-month follow-up, while use of an alarm device had no effect. As antiretroviral treatment clinics expand to meet an increasing demand for HIV care in sub-Saharan Africa, adherence counseling should be implemented to decrease the development of treatment failure and spread of resistant HIV.

Trial registration:
ClinicalTrials gov NCT00273780

: Please see later in the article for the Editors' Summary

Vyšlo v časopise: A Randomized Controlled Trial Comparing the Effects of Counseling and Alarm Device on HAART Adherence and Virologic Outcomes. PLoS Med 8(3): e32767. doi:10.1371/journal.pmed.1000422
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1000422

Souhrn

Trial registration:
ClinicalTrials gov NCT00273780

: Please see later in the article for the Editors' Summary

Zdroje

1. HarriesAD

NyanguluDS

HargreavesNJ

KaluwaO

SalaniponiFM

2001 Preventing antiretroviral anarchy in sub-Saharan Africa. Lancet 358 410 414

2. CarlucciJG

KamangaA

ShenebergerR

ShepherdBE

JenkinsCA

2008 Predictors of adherence to antiretroviral therapy in rural Zambia. J Acquir Immune Defic Syndr 47 615 622

3. OrrellC

BangsbergDR

BadriM

WoodR

2003 Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS 17 1369 1375

4. MillsEJ

NachegaJB

BuchanI

OrbinskiJ

AttaranA

2006 Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 296 679 690

5. CalmyA

PinogesL

SzumilinE

ZachariahR

FordN

2006 Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS 20 1163 1169

6. Wools-KaloustianK

KimaiyoS

DieroL

SiikaA

SidleJ

2006 Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. AIDS 20 41 48

7. StringerJS

ZuluI

LevyJ

StringerEM

MwangoA

2006 Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 296 782 793

8. CresseyTR

JourdainG

LallemantMJ

KunkeawS

JacksonJB

2005 Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr 38 283 288

9. MartinM

Del CachoE

CodinaC

TusetM

De LazzariE

2008 Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study. AIDS Res Hum Retroviruses 24 1263 1268

10. BangsbergDR

2006 Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 43 939 941

11. PatersonDL

SwindellsS

MohrJ

BresterM

VergisEN

2000 Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 133 21 30

12. MaggioloF

RavasioL

RipamontiD

GregisG

QuinzanG

2005 Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis 40 158 163

13. NachegaJB

HislopM

DowdyDW

ChaissonRE

RegensbergL

2007 Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med 146 564 573

14. FordN

NachegaJB

EngelME

MillsEJ

2009 Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials. Lancet 374 2064 2071

15. NachegaJB

MillsEJ

SchechterM

Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities. Curr Opin HIV AIDS 5 70 77

16. KatabiraET

OelrichsRB

2007 Scaling up antiretroviral treatment in resource-limited settings: successes and challenges. AIDS 21 Suppl 4 S5 10

17. WagnerG

RyanG

TaylorS

2007 Formative evaluation of antiretroviral therapy scale-up efficiency in sub-Saharan Africa. AIDS Patient Care STDS 21 871 888

18. FerradiniL

JeanninA

PinogesL

IzopetJ

OdhiamboD

2006 Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 367 1335 1342

19. SevereP

LegerP

CharlesM

NoelF

BonhommeG

2005 Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 353 2325 2334

20. BehforouzHL

FarmerPE

MukherjeeJS

2004 From directly observed therapy to accompagnateurs: enhancing AIDS treatment outcomes in Haiti and in Boston. Clin Infect Dis 38 Suppl 5 S429 436

21. RuedaS

Park-WyllieLY

BayoumiAM

TynanAM

AntoniouTA

2006 Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. Cochrane Database Syst Rev 3 CD001442

22. SimoniJM

PearsonCR

PantaloneDW

MarksG

CrepazN

2006 Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load. A meta-analytic review of randomized controlled trials. J Acquir Immune Defic Syndr 43 Suppl 1 S23 S35

23. PearsonCR

MicekMA

SimoniJM

HoffPD

MatedianaE

2007 Randomized control trial of peer-delivered, modified directly observed therapy for HAART in Mozambique. J Acquir Immune Defic Syndr 46 238 244

24. SarnaA

LuchtersS

GeibelS

ChersichMF

MunyaoP

2008 Short- and long-term efficacy of modified directly observed antiretroviral treatment in Mombasa, Kenya: a randomized trial. J Acquir Immune Defic Syndr 48 611 619

25. McNeilDGJ

2010 July 22 Drug war statement upstaged at AIDS gathering. The New York Times

26. McNeilDGJ

2010 May 9 As the need grows, the money for AIDS runs far short. The New York Times

27. McNeilDGJ

2010 May 10 At front lines, global war on AIDS is falling apart. The New York Times

28. FrickP

TapiaK

GrantP

NovotnyM

KerzeeJ

2006 The effect of a multidisciplinary program on HAART adherence. AIDS Patient Care STDS 20 511 524

29. FrickPA

LavreysL

MandaliyaK

KreissJK

2001 Impact of an alarm device on medication compliance in women in Mombasa, Kenya. Int J STD AIDS 12 329 333

30. ChungMH

DrakeAL

RichardsonBA

ReddyA

ThigaJ

2009 Impact of prior HAART use on clinical outcomes in a large Kenyan HIV treatment program. Curr HIV Res 7 441 446

31. OjooS

2007 Kenya national clinical manual for ART providers: a concise and practical guide to ART provision.2nd edition. Nairobi National AIDS and STI Control Program (NASCOP) 70

32. FisherJD

FisherWA

MisovichSJ

KimbleDL

MalloyTE

1996 Changing AIDS risk behavior: effects of an intervention emphasizing AIDS risk reduction information, motivation, and behavioral skills in a college student population. Health Psychol 15 114 123

33. MillerWR

RoseGS

2009 Toward a theory of motivational interviewing. Am Psychol 64 527 537

34. EmeryS

BodrugS

RichardsonBA

GiachettiC

BottMA

2000 Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya. J Clin Microbiol 38 2688 2695

35. World Health Organization 2010 Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Geneva World Health Organization Press

36. PocockSJ

AssmannSE

EnosLE

KastenLE

2002 Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med 21 2917 2930

37. TuldraA

FumazCR

FerrerMJ

BayesR

ArnoA

2000 Prospective randomized two-Arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 25 221 228

38. MannheimerS

FriedlandG

MattsJ

ChildC

ChesneyM

2002 The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis 34 1115 1121

39. SethiAK

CelentanoDD

GangeSJ

MooreRD

GallantJE

2003 Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 37 1112 1118

40. MannheimerSB

MorseE

MattsJP

AndrewsL

ChildC

2006 Sustained benefit from a long-term antiretroviral adherence intervention. Results of a large randomized clinical trial. J Acquir Immune Defic Syndr 43 Suppl 1 S41 47

41. RathbunRC

FarmerKC

StephensJR

LockhartSM

2005 Impact of an adherence clinic on behavioral outcomes and virologic response in treatment of HIV infection: a prospective, randomized, controlled pilot study. Clin Ther 27 199 209

42. PradierC

BentzL

SpireB

Tourette-TurgisC

MorinM

2003 Efficacy of an educational and counseling intervention on adherence to highly active antiretroviral therapy: French prospective controlled study. HIV Clin Trials 4 121 131

43. CoopermanNA

ArnstenJH

2005 Motivational interviewing for improving adherence to antiretroviral medications. Curr HIV/AIDS Rep 2 159 164

44. WattMH

MamanS

EarpJA

EngE

SetelPW

2009 “It's all the time in my mind”: facilitators of adherence to antiretroviral therapy in a Tanzanian setting. Soc Sci Med 68 1793 1800

45. WiseJ

OperarioD

2008 Use of electronic reminder devices to improve adherence to antiretroviral therapy: a systematic review. AIDS Patient Care STDS 22 495 504

46. SimoniJM

HuhD

FrickPA

PearsonCR

AndrasikMP

2009 Peer support and pager messaging to promote antiretroviral modifying therapy in Seattle: a randomized controlled trial. J Acquir Immune Defic Syndr 52 465 473

47. LesterRT

RitvoP

MillsEJ

KaririA

KaranjaS

2010 Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet 376 1838 1845

48. DonnellyJ

2001 June 7 Prevention urged in AIDS fight; Natsios says funds should spend less on HIV treatment. Boston Globe

49. AmicoKR

HarmanJJ

JohnsonBT

2006 Efficacy of antiretroviral therapy adherence interventions: a research synthesis of trials, 1996 to 2004. J Acquir Immune Defic Syndr 41 285 297

50. ChungMH

KohlerP

AttwaM

ThigaJ

John-StewartGC

2010 Comparing clinic retention between residents and nonresidents of Kibera, Kenya. J Acquir Immune Defic Syndr 53 422 424

51. OsterbergL

BlaschkeT

2005 Adherence to medication. N Engl J Med 353 487 497

52. GillCJ

HamerDH

SimonJL

TheaDM

SabinLL

2005 No room for complacency about adherence to antiretroviral therapy in sub-Saharan Africa. AIDS 19 1243 1249

53. MellorsJW

RinaldoCRJr.

GuptaP

WhiteRM

ToddJA

1996 Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272 1167 1170

54. AldousJL

HaubrichRH

2009 Defining treatment failure in resource-rich settings. Curr Opin HIV AIDS 4 459 466

55. HosseinipourMC

van OosterhoutJJ

WeigelR

PhiriS

KamwendoD

2009 The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 23 1127 1134